About Repinex XL

Welcome to

Repinex XL® is a prolonged-release tablet of ropinirole indicated for the treatment of Parkinson’s disease under the following conditions:1

  • Initial treatment as monotherapy, in order to delay the introduction of levodopa
  • In combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur (“end of dose” or “on-off” type fluctuations).

Available as:

  • 2mg prolonged-release tablets

  • 4mg prolonged-release tablets

  • 8mg prolonged-release tablets

Repinex XL is bioequivalent to Requip® (ropinirole) XL tablets (GlaxoSmithKline, Brentford, UK)2

Repinex XL could offer significant cost savings to your practice and clinical commissioning group (CCG).

Ropinirole 2mg, 4mg and 8mg prolonged-release tablets are in category C of the UK Drug Tariff.3

However, the NHS could make 50% savings on the cost of category C ropinirole by prescribing Repinex XL by brand name.3*

Quite simply a wholesale switch of ropinirole 2mg, 4mg and 8mg prolonged-release prescriptions to Repinex XL could still save an average ICS/ICB £49,475 per year.4**

Repinex XL is one of Aspire Pharma’s cost saving prolonged-release products.

In addition Repinex XL:

  • Available from mainline wholesalers;

  • High level of stockholdings;

  • Bioequivalent to the originator brand;2

  • Price guaranteed***

*50% saving on the cost of Category C ropinirole prolonged-release tablets in the UK Drug Tariff. **Savings based on market data in reference 4 for 42 ICS/ICB’s switching their generic and brand originator 2,4 and 8mg ropinirole prolonged-release tablet prescriptions to Repinex XL. ***No change in price subject to no material change to the products or Category C of the UK Drug Tariff until the 2026 VPAG review.
References: 1) Repinex XL SmPCs. 2) Data on file. 1010067149 v 6.0 September 2023. 3) February 2024 UK Drug Tariffs. 4) Insypher 10100831045 v 17.0 January 2024 GPPLPD Date Range: Jul-23 – Sep-23 


For further information please call: 01730 231148,
email: [email protected] or visit
Adverse events should be reported. Reporting forms and information can be found at
Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148

For more information about Repinex XL, please click here for the prescribing information.

Revision reference – Repinex XL_24_01.02.24

More products available
in this range:
Click to view their
individual websites